1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Patient Monitoring Device Market Trends
  5. > Neuromodulation Devices Global Market – Forecast To 2021

Neuromodulation Devices Global Market – Forecast To 2021

  • December 2015
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 256 pages

Summary

The neuromodulation technology utilizes devices that bring about a change in nervous system either by stimulation or modulating brain activity. The treatment delivered by neuromodulation devices brings about life changing transformation in patients who fail to get better by traditional approaches. The opportunities to development new therapies for a wide variety of neurological and psychological conditions are attracting lot of companies, start ups and investments. According to IQ4I analysis, the global neuromodulation devices market is expected to grow at a double digit CAGR to reach $9.3 billion by 2021.

Factors driving the neuromodulation market include, projected increase in patients with chronic pain, neurodegenerative diseases, psychiatric conditions, improvements in technology such as miniaturization, better battery technology, use of bioactive coatings are all contributing for growth of neuromodulation devices market whereas risk of side effects, availability of alternative treatment and high initial cost of implants are the factors hampering the market growth. Advancement of technology with its wide application areas shows that neuromodulation devices market has vast opportunities in the coming years.

Neuromodulation devices market is segmented on the basis of technology as internal and external neuromodulation. The internal neuromodulation is again classified into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS) and Other with Gastric Electric Stimulation (GES) and Respiratory Electrical Stimulation (RES)/Phrenic Nerve Stimulation (PNS). Based on the application the neuromodulation devices market is segmented into Chronic Pain, Movement Disorders, Psychiatric Conditions, Gastroenterology & Urology and other applications. Based on end-users the market is segmented into hospitals and private neuromodulation clinics.

North America accounts for the highest market share of 56.1% followed by Europe. Steep rise in ageing population, advancement in technology, awareness of people and favourable government policies makes U.S. the leader of neuromodulation devices market. However, Asian countries especially India and China are the fast growing regions with its growing demand for neuromodulation devices.

Major players in Neuromodulation devices market include Medtronic (Ireland), Boston Scientific (U.S.), Cyberonics (U.S.), St. Jude Medical (U.S.), Neurometrix, Inc (U.S.), Neuronetics, Inc (U.S.), Nevro Corporation (U.S.), Synapse Biomedical (U.S.), Avery Biomedical (U.S.) and Magstim (U.K.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Table Of Contents

Neuromodulation Devices Global Market - Forecast To 2021

1 EXECUTIVE SUMMARY 22
2 INTRODUCTION 27
2.1 KEY TAKE AWAYS 27
2.2 REPORT DESCRIPTION 28
2.3 MARKETS COVERED 29
2.4 STAKEHOLDERS 31
2.5 RESEARCH METHODOLOGY 31
2.5.1 MARKET SIZE ESTIMATION 33
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.5.3 SECONDARY SOURCES 37
2.5.4 PRIMARY SOURCES 37
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 38
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 39
2.5.7 ASSUMPTIONS 39
3 MARKET ANALYSIS 41
3.1 INTRODUCTION 41
3.2 MARKET SEGMENTATION 42
3.3 FACTORS INFLUENCING MARKET 44
3.3.1 DRIVERS AND OPPORTUNTIES 45
3.3.1.1 Aging population and increase in chronic diseases such as Parkinson's and Alzheimer's disorders. 45
3.3.1.2 Low approval rate and Cuts in RandD budget of CNS drugs to drive neuromodulation market 46
3.3.1.3 Emergence of neuromodulation as add on therapy 46
3.3.1.4 Technology innovations and increased investments in neuromodulation. 47
3.3.1.5 Expansion in Emerging markets 47
3.3.2 RESTRAINTS AND THREATS 48
3.3.2.1 Side effects and risks associated with the use 48
3.3.2.2 Availability of alternative treatments 48
3.3.3 BURNING ISSUE 49
3.3.3.1 Lack of trained professionals 49
3.4 REGULATORY AFFAIRS 49
3.4.1 U.S. 49
3.4.2 EUROPE 50
3.4.3 CHINA 51
3.4.4 CANADA 51
3.4.5 INDIA 52
3.5 REIMBURSEMENT SCENARIO 53
3.6 PATENT ANALYSIS 54
3.7 TECHNOLOGICAL ADVANCEMENTS 55
3.7.1 RECHARGEABLE SYSTEMS 56
3.7.2 OPTOGENETIC TECHNOLOGY 56
3.7.3 ULTRASONIC STIMULATION 56
3.7.4 MINIATURIZATION 57
3.7.5 PORTABLE NUEROMODULATION SYSTEMS (PONS) 58
3.7.6 WEARABLE PAIN MANAGEMENT TECHNOLOGY 58
3.7.7 TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS) 58
3.7.8 NANO-NEUROMODULATION 59
3.7.9 BIOACTIVE COATINGS 59
3.8 UPCOMING TECHNOLOGIES 60
3.9 PORTER'S FIVE FORCE ANALYSIS 63
3.9.1 THREAT OF NEW ENTRANTS 64
3.9.2 THREAT OF SUBSTITUTES 65
3.9.3 BARGAINING POWER OF SUPPLIERS 65
3.9.4 BARGAINING POWER OF BUYERS 65
3.9.5 RIVALRY AMONG EXISTING COMPETITORS 66
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 67
4 NEUROMODULATION DEVICES GLOBAL MARKET, BY TECHNOLOGY 70
4.1 INTRODUCTION 70
4.2 INTERNAL NEUROMODULATION 73
4.2.1 SPINAL CORD STIMULATION (SCS) 77
4.2.2 DEEP BRAIN STIMULATION (DBS) 79
4.2.3 VAGUS NERVE STIMULATION (VNS) 80
4.2.4 SACRAL NERVE STIMULATION (SNS) 82
4.2.5 OTHERS 84
4.2.5.1 Gastric electric stimulation (GES) 85
4.2.5.2 Respiratory electrical stimulation (RES)/Phrenic nerve stimulation 85
4.3 EXTERNAL NEUROMODULATION 86
4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 90
4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 92
5 GLOBAL NEUROMODULATION DEVICES MARKET, BY APPLICATIONS 94
5.1 INTRODUCTION 94
5.2 CHRONIC PAIN 97
5.2.1 FAILED BACK SURGERY SYNDROME (FBSS) 98
5.2.2 ISCHEMIA 99
5.2.3 MIGRAINE 100
5.3 MOVEMENT DISORDERS 100
5.3.1 PARKINSON'S DISEASE 102
5.3.2 ESSENTIAL TREMORS 103
5.3.3 DYSTONIA 104
5.3.4 EPILEPSY OR SEIZURE 105
5.4 PSYCHIATRIC CONDITION 106
5.4.1 DEPRESSION 108
5.4.2 OBSESSIVE COMPULSIVE DISORDER (OCD) 109
5.5 GASTROENTEROLOGY AND UROLOGY 110
5.5.1 GASTROPARESIS 112
5.5.2 URINARY INCONTINENCE 112
5.5.3 FAECAL INCONTINENCE 113
5.6 OTHERS 114
5.6.1 OBESITY 116
5.6.2 DIAPHRAGM PACING 117
6 NEUROMODULATION DEVICES GLOBAL MARKET, BY END-USERS 118
6.1 INTRODUCTION 118
6.2 HOSPITALS 121
6.3 PRIVATE CLINICS/THERAPY CENTERS 123
7 REGIONAL ANALYSIS 125
7.1 INTRODUCTION 125
7.2 NORTH AMERICA 128
7.3 EUROPE 135
7.4 ASIA- PACIFIC 142
7.5 REST OF THE WORLD 149
8 COMPANY DEVELOPMENTS 156
8.1 INTRODUCTION 156
8.2 APPROVALS 157
8.3 AGREEMENTS and COLLOBORATIONS 164
8.4 NEW PRODUCT LAUNCHES 168
8.5 MERGERS and ACQUISITIONS 171
8.6 OTHERS 175
9 COMPANY PROFILES 182
9.1 AVERY BIOMEDICAL DEVICES, INC 182
9.1.1 OVERVIEW 182
9.1.2 FINANCIALS 182
9.1.3 PRODUCT PORTFOLIO 183
9.1.4 KEY DEVELOPMENTS 183
9.1.5 BUSINESS STRATEGIES 183
9.1.6 SWOT ANALYSIS 184
9.2 BOSTON SCIENTIFIC CORPOARTION 185
9.2.1 OVERVIEW 185
9.2.2 FINANCIALS 186
9.2.3 PRODUCT PORTFOLIO 189
9.2.4 KEY DEVELOPMENTS 190
9.2.5 BUSINESS STRATEGY 192
9.2.6 SWOT ANALYSIS 193
9.3 COGENTIX MEDICAL (UROPLASTY, INC) 194
9.3.1 OVERVIEW 194
9.3.2 FINANCIALS 195
9.3.3 PRODUCT PORTFOLIO 196
9.3.4 KEY DEVELOPMENTS 197
9.3.5 BUSINESS STRATEGY 198
9.3.6 SWOT ANALYSIS 199
9.4 CYBERONICS, INC (LIVANOVA) 200
9.4.1 OVERVIEW 200
9.4.2 FINANCIALS 201
9.4.3 PRODUCT PORTFOLIO 202
9.4.4 KEY DEVELOPMENTS 203
9.4.5 BUSINESS STRATEGY 204
9.4.6 SWOT ANALYSIS 204
9.5 MAGSTIM COMPANY LTD 205
9.5.1 OVERVIEW 205
9.5.2 FINANCIALS 205
9.5.3 PRODUCT PORTFOLIO 206
9.5.4 SERVICES 206
9.5.5 KEY DEVELOPMENTS 207
9.5.6 BUSINESS STRATEGIES 207
9.5.7 SWOT ANALYSIS 208
9.6 MEDTRONIC, PLC 209
9.6.1 OVERVIEW 209
9.6.2 FINANCIALS 210
9.6.3 PRODUCT PORTFOLIO 214
9.6.4 KEY DEVELOPMENTS 215
9.6.5 BUSINESS STRATEGY 219
9.6.6 SWOT ANALYSIS 220
9.7 NEUROMETRIX, INC 221
9.7.1 OVERVIEW 221
9.7.2 FINANCIALS 222
9.7.3 PRODUCT PORTFOLIO 224
9.7.4 KEY DEVELOPMENTS 225
9.7.5 BUSINESS STRATEGY 228
9.7.6 SWOT ANALYSIS 229
9.8 NEURONETICS, INC 230
9.8.1 OVERVIEW 230
9.8.2 FINANCIALS 230
9.8.3 PRODUCT PORTFOLIO 231
9.8.4 KEY DEVELOPMENTS 231
9.8.5 BUSINESS STRATEGY 232
9.8.6 SWOT ANALYSIS 233
9.9 NEUROPACE, INC, 233
9.9.1 OVERVIEW 234
9.9.2 FINANCIALS 234
9.9.3 PRODUCT PORTFOLIO 234
9.9.4 KEY DEVELOPMENTS 235
9.9.5 BUSINESS STRATEGIES 236
9.9.6 SWOT ANALYSIS 236
9.10 NEVRO CORPORATION 237
9.10.1 OVERVIEW 238
9.10.2 FINANCIALS 238
9.10.3 PRODUCT PORTFOLIO 240
9.10.4 KEY DEVELOPMENTS 241
9.10.5 BUSINESS STRATEGY 241
9.10.6 SWOT ANALYSIS 242
9.11 ST. JUDE MEDICAL, INC 243
9.11.1 OVERVIEW 243
9.11.2 FINANCIALS 244
9.11.3 PRODUCT PORTFOLIO 247
9.11.4 KEY DEVELOPMENTS 248
9.11.5 BUSINESS STRATEGY 251
9.11.6 SWOT ANALYSIS 252
9.12 SYNAPSE BIOMEDICAL, INC 253
9.12.1 OVERVIEW 253
9.12.2 FINANCIALS 253
9.12.3 PRODUCT PORTFOLIO 254
9.12.4 KEY DEVELOPMENTS 254
9.12.5 BUSINESS STRATEGY 255
9.12.6 SWOT ANALYSIS 255











LIST OF TABLES

TABLE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 26
TABLE 2 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 71
TABLE 3 INTERNAL NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 74
TABLE 4 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 75
TABLE 5 SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 78
TABLE 6 DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 80
TABLE 7 VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE,
BY REGION, (2013-2021) ($MN) 82
TABLE 8 SACRAL NERVE STIMULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 83
TABLE 9 OTHERS INTERNAL NEUROMODULATION GLOBAL MARKET REVENUE,
BY REGION, (2013-2021) ($MN) 84
TABLE 10 EXTERNAL NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 87
TABLE 11 EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 88
TABLE 12 TENS NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 91
TABLE 13 TMS NEUROMODULATION GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 93
TABLE 14 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY APPLICATION, (2013-2021) ($MN) 96
TABLE 15 CHRONIC PAIN GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 98
TABLE 16 MOVEMENT DISORDERS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 101
TABLE 17 PSYCHIATRIC DISORDERS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 107
TABLE 18 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE,
BY REGION, (2013-2021) ($MN) 111
TABLE 19 OTHERS NEUROMODULATION STIMULATION GLOBAL MARKET REVENUE,
BY REGION, (2013-2021) ($MN) 115
TABLE 20 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END-USERS, (2013-2021) ($MN) 119
TABLE 21 HOSPITALS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 122
TABLE 22 PRIVATE CLINICS/THERAPY CENTERS GLOBAL MARKET REVENUE,
BY REGION, (2013-2021) ($MN) 124
TABLE 23 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 127
TABLE 24 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 130
TABLE 25 NORTH AMERICAN INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN) 131
TABLE 26 NORTH AMERICAN EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN) 132
TABLE 27 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE,
BY APPLICATION, (2013-2021) ($MN) 133
TABLE 28 NORTH AMERICAN NEUROMODULATION DEVICES MARKET REVENUE,
BY END USER, (2013-2021) ($MN) 134
TABLE 29 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 137
TABLE 30 EUROPEAN INTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 138
TABLE 31 EUROPEAN EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 139
TABLE 32 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE,
BY APPLICATION, (2013-2021) ($MN) 140
TABLE 33 EUROPEAN NEUROMODULATION DEVICES MARKET REVENUE,
BY END USER, (2013-2021) ($MN) 141
TABLE 34 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 144
TABLE 35 ASIA-PACIFIC INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN) 145
TABLE 36 ASIA PACIFIC EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN) 146
TABLE 37 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE,
BY APPLICATION, (2013-2021) ($MN) 147
TABLE 38 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET REVENUE,
BY END USER, (2013-2021) ($MN) 148
TABLE 39 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY TECHNOLOGY, (2013-2021) ($MN) 151
TABLE 40 ROW INTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 152
TABLE 41 ROW EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE,
BY TECHNOLOGY, (2013-2021) ($MN) 153
TABLE 42 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 154
TABLE 43 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY END USER, (2013-2021) ($MN) 155
TABLE 44 APPROVALS (2013-2015) 158
TABLE 45 AGREEMENT AND COLLABORATION (2013-2015) 165
TABLE 46 NEW PRODUCT LAUNCHES (2013-2015) 169
TABLE 47 MERGERS and ACQUISTIONS (2013-2015) 172
TABLE 48 OTHERS (2013-2015) 175
TABLE 49 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 186
TABLE 50 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE BY SEGMENTS, (2012-14) ($MN) 187
TABLE 51 BOSTON SCIENTIFIC CORPORATION: MEDSURG REVENUE, BY SEGMNETS (2012-2014) ($MN) 188
TABLE 52 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE BY GEOGRAPHY (2012-2014) ($MN) 189
TABLE 53 COGENTIX MEDICAL: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 195
TABLE 54 COGENTIX MEDICAL: TOTAL REVENUE, BY GEOGRAPHY,
(2012-2014) ($MN) 196
TABLE 55 CYBERONICS, INC: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 201
TABLE 56 CYBERONICS, INC: TOTAL REVENUE BY GEOGRAPHY (2012-2014) ($MN) 202
TABLE 57 MEDTRONIC, PLC : TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 210
TABLE 58 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2012-2014) ($MN) 211
TABLE 59 MEDTRONIC, PLC: RESTORATIVE THERAPY REVENUE, BY SUB-SEGMENTS, (2012-2014) ($MN) 212
TABLE 60 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 213
TABLE 61 NEUROMETRIX : TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 222
TABLE 62 NEUROMETRIX: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 223
TABLE 63 NEUROMETRIX: TOTAL REVENUE BY PRODUCTS, (2012-14) ($MN) 224
TABLE 64 NEVRO CORP.: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 238
TABLE 65 NEVRO CORP: TOTAL REVENUE BY GEOGRAPHY, (2012-2014) ($MN) 239
TABLE 66 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 244
TABLE 67 ST. JUDE MEDICAL, INC: TOTAL REVENUE BY SEGMENTS, (2012-14) ($MN) 245
TABLE 68 ST. JUDE MEDICAL, INC: TOTAL REVENUE BY GEOGRAPHY,
(2012-2014) ($MN) 246





















LIST OF FIGURES


FIGURE 1 NEUROMODULATON DEVICES GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 25
FIGURE 2 RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET 32
FIGURE 3 NEUROMODULATION DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 33
FIGURE 4 NEUROMODULATION DEVICES MARKET: FORECASTING MODEL 35
FIGURE 5 NEUROMODULATION DEVICES MARKET: MARKET BREAKDOWN and DATA TRIANGULATION 36
FIGURE 6 NEUROMODULATION DEVICES MARKET SEGMENTATION 43
FIGURE 7 MARKET DYNAMICS 44
FIGURE 8 NEUROMOUDLATION DEVICES MARKET:PCT APPLICATIONS FILING BY MAJOR PLAYERS (2011-2015) 54
FIGURE 9 NEUROMODULATION DEVICES MARKET: PORTER'S ANALYSIS 64
FIGURE 10 GLOBAL NEUROMODULATION DEVICES MARKET SHARE,
BY MAJOR PLAYERS (2014) 67
FIGURE 11 NEUROMODULATION DEVICES GLOBAL REVENUE, BY TECHNOLOGY
(2014 V'S 2021) ($MN) 72
FIGURE 12 INTERNAL NEUROMODULATION DEVICES GLOBAL REVENUE,
BY TECHNOLOGY (2014 V'S 2021) ($MN) 76
FIGURE 13 EXTERNAL NEUROMODULATION DEVICES GLOBAL REVENUE,
BY TECHNOLOGY (2014 V'S 2021) ($MN) 89
FIGURE 14 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE,
BY APPLICATION (2014 V'S 2021) ($MN) 95
FIGURE 15 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END USERS (2014 V'S 2021) ($MN) 120
FIGURE 16 NEUROMODULATON DEVICES GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 126
FIGURE 17 NORTH AMERICAN NEUROMODULATION DEVICES MARKET SIZE,
BY TECHNOLOGY, APPLICATION and END-USER (2014 V'S 2021) ($MN) 129
FIGURE 18 EUROPEAN NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION and END-USER (2014 V'S 2021) ($MN) 136
FIGURE 19 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE,
BY TECHNOLOGY, APPLICATION and END-USER (2014 V'S 2021) ($MN) 143
FIGURE 20 ROW NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, APPLICATION and END-USER (2014 V'S 2021) ($MN) 150
FIGURE 21 KEY GROWTH STRATEGIES (2013-2015) 157
FIGURE 22 SWOT: AVERY BIOMEDICAL DEVICES, INC 184
FIGURE 23 SWOT: BOSTON SCIENTIFIC CORPORATION 193
FIGURE 24 SWOT: COGENTIX MEDICAL 199
FIGURE 25 SWOT: CYBERONICS, INC 204
FIGURE 26 SWOT: MAGSTIM COMPANY LIMITED 208
FIGURE 27 SWOT: MEDTRONIC, PLC 220
FIGURE 28 SWOT: NEUROMETRIX, INC 229
FIGURE 29 SWOT: NEURONETICS, INC 233
FIGURE 30 SWOT: NEUROPACE, INC 236
FIGURE 31 SWOT: NEVRO CORP 242
FIGURE 32 SWOT: ST. JUDE MEDICAL, INC 252
FIGURE 33 SWOT: SYNAPSE BIOMEDICAL, INC 255

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
US Market Report for Neuromodulation Devices 2017 - MedCore

US Market Report for Neuromodulation Devices 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description Market growth will be propelled by wider acceptance of neuromodulation products, allowing them to be used on a larger proportion of potential patients. In addition, many neuromodulation patients ...

United States Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report

United States Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report

  • $ 3800
  • Industry report
  • April 2016
  • by QY Research Group

The United States Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Neuromodulation Devices And ...

Global Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report

Global Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report

  • $ 2800
  • Industry report
  • April 2016
  • by QY Research Group

The Global Neuromodulation Devices And Implantable Infusion Pumps Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Neuromodulation Devices And Implantable ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.